Cliniphar (TSE:432A) EPS (Basic): 円161.01 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:432A Cliniphar Ltd TSE:432A
20 GF Score
Price 円1,450.00
! 3 Warning Signs
View Full Analysis

What is Cliniphar EPS (Basic)?

Cliniphar TSE:432A 20 EPS (Basic) is 円161.01 as of Mar. 2026. GuruFocus rates TSE:432A with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Cliniphar's basic earnings per share (Basic EPS) for the six months ended in Mar. 2026 was 円78.29. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was 円161.01.

Cliniphar's EPS (Diluted) for the six months ended in Mar. 2026 was 円78.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円161.01.

Cliniphar's EPS without NRI for the six months ended in Mar. 2026 was 円79.18. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 170.50.

During the past 12 months, Cliniphar's average EPS without NRIGrowth Rate was 1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cliniphar  (TSE:432A) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cliniphar EPS (Basic) Related Terms

Cliniphar EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Cliniphar's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cliniphar EPS (Basic) Chart

Cliniphar Annual Data
Trend Mar24 Mar25 Mar26
EPS (Basic)
-613.40 190.26 161.01

Cliniphar Semi-Annual Data
Mar24 Mar25 Sep25 Mar26
EPS (Basic) 0.00 0.00 82.72 78.29
TSE:432A
20GF Score
Cliniphar Ltd TSE:432A
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cliniphar EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cliniphar's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(161.012-0)/1.000
=161.01

Cliniphar's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(78.289-0)/1.000
=78.29

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円161.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of 円161.01 mean?
Cliniphar (TSE:432A) has a EPS (Basic) of 円161.01 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cliniphar and its competitors.
Is Cliniphar's EPS (Basic) too high?
Cliniphar's current EPS (Basic) is 円161.01. Overall, Cliniphar has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cliniphar's EPS (Basic) compare to competitors?
Cliniphar's EPS (Basic) of 円161.01 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Healthcare Providers & Services company?
A good EPS (Basic) depends on the Healthcare Providers & Services industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Cliniphar and its competitors. Cliniphar's current EPS (Basic) is 円161.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cliniphar stock overvalued right now?
Cliniphar (TSE:432A) has a current EPS (Basic) of 円161.01. The current EPS (Basic) is 円161.01. Cliniphar's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Cliniphar (TSE:432A), the current EPS (Basic) is 円161.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cliniphar Business Description

Address 1-7-31, Otemae, 5th Floor, OMM Building, Otemae, Chuo-ku, Osaka-shi, Osaka, JPN, 540-0008
Cliniphar Ltd is engaged in Pharmaceutical Wholesale and Distribution Business for Domestic and International Markets.
20GF Score

Get the complete analysis for TSE:432A

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,450.00
Price